<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036229</url>
  </required_header>
  <id_info>
    <org_study_id>topical ivermectin, demodex</org_study_id>
    <nct_id>NCT02036229</nct_id>
  </id_info>
  <brief_title>Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis</brief_title>
  <official_title>a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 0.5% ivermectin cream is effective in the
      treatment of demodicidosis (including papulopustular rosacea)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A decrease in mite density in skin surface biopsy after treatment with topical ivermectin (â‰¤5 mites/cm2   for skin lesions).</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical improvement will be assessed by objective evaluation of erythema, dryness, scaling, roughness, and/or papules/pustules in skin lesions and subjective evaluation of itch and dryness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A comparable dermoscopic improvement in the demodicidosis features</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>dermoscopic demodicidosis features:
number of demodex tails
demodex follicular openings
reticular dilated vessels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Demodex</condition>
  <condition>Demodicidosis</condition>
  <condition>Topical Ivermectin</condition>
  <arm_group>
    <arm_group_label>0.5% ivermectin cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin cream 0.5%</intervention_name>
    <description>Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.</description>
    <arm_group_label>0.5% ivermectin cream</arm_group_label>
    <arm_group_label>vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with clinical and laboratory diagnosis of demodicidosis with symmetrical
             facial eruption who are willing to comply with study requirements

        Exclusion Criteria:

          -  known hypersensitivity to ivermectin.

          -  pregnancy

          -  immunodeficiency such as HIV or immunosuppressive therapy

          -  concomitant use of systemic antibiotics or steroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rina Segal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rina Segal, MD</last_name>
    <phone>972505206134</phone>
    <email>rinas3@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>RabinMC, Dermatology dept.</name>
      <address>
        <city>Petah-Tiqva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rina Segal, MD</last_name>
      <phone>972505206134</phone>
    </contact>
    <investigator>
      <last_name>Rina Segal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Rina Segal</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>demodex</keyword>
  <keyword>demodicidosis</keyword>
  <keyword>rosacea</keyword>
  <keyword>ivermectin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
